Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health ...

Characterised by the abnormal accumulation of two proteins, amyloid beta and phosphorylated tau (pTau), AD progresses ...

The figures show that ADHD medicine prescriptions have seen the steepest rise, particularly since 2020/21. Last year, 278,000 ...

AZ said adding YS2302018 to its pipeline strengthens its cardiovascular portfolio with a drug that could have potential in a ...

UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific ...

The phase 3b BATURA study showed Airsupra (albuterol/budesonide) achieved a statistically significant reduction in the risk of severe asthma exacerbations when used as needed for rescue therapy ...

The week has started with reports that activist investor Starboard Value has amassed a $1 billion stake in pharma group ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

In the ever-evolving landscape of healthcare, the concept of value-based care (VBC) has gained substantial momentum in recent years. It represents a significant shift from the traditional fee-for ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...